The development and deployment of implantable brain-computer interfaces (iBCIs) will succeed only if we prioritize the end users—individuals who will ultimately benefit from these technologies. This Workgroup seeks to ensure that iBCIs align with the needs, preferences, and daily realities of potential users, who may include individuals living with neurological conditions and care partners. By understanding the specific preferences of people representing potential populations who could benefit from iBCIs, and by incorporating these preferences into the design and testing of iBCIs, iBCIs are more likely to be viewed as effective solutions and adopted by potential users. Building a robust evidence base for the use cases of each identified population is essential to guide product development, clinical trials, regulatory approvals, and payor pathways, ensuring that iBCIs are not only effective but also user-centered.

This Workgroup is focusing first on the populations of people with neurologic injury or disease for whom there is already experience with iBCI clinical trials and preliminary evidence of efficacy, anticipating that current and upcoming clinical trials will build on this background. The Workgroup will then expand its scope to include the many additional populations who may benefit.